Product Description
Mechanisms of Action: APM1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chroma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Acute Myeloid Leukemia|Myelodysplastic Syndrome
Phase 2: Acute Myeloid Leukemia|Adenocarcinoma|Multiple Myeloma|Pancreatic Cancer|Myelodysplastic Syndrome|Preleukemia|Leukemia, Plasma Cell|Non-Small-Cell Lung Cancer|Anemia, Refractory, with Excess of Blasts
Phase 1: Myelodysplastic Syndrome|Acute Myeloid Leukemia|Oncology Solid Tumor Unspecified|Preleukemia|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2006-7041-83/hah | N/A |
Not yet recruiting |
Surgical Wound Infection |
2020-05-04 |
|
| NCI-2018-01817 | P1 |
Terminated |
Preleukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome |
2019-07-04 |
|
| LI-1 | P3 |
Unknown status |
Myelodysplastic Syndrome|Acute Myeloid Leukemia |
2019-05-04 |
|
| MUK three | P2 |
Completed |
Multiple Myeloma |
2017-10-30 |